PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Haloperidol Supported for ICU Delirium Treatment, Not Prevention

haloperidolantipsychoticsdeliriumICUcritical caremortalitybenzodiazepine sparingQTc prolongationBayesian meta-analysissedation Critical Care / ICU

Background Information

Haloperidol effective for delirium symptoms, not for prevention or mortality.

Delirium is a common and serious issue in critical care settings that impacts patient outcomes and mortality. Both Bayesian and frequentist meta-analyses suggest that haloperidol does not significantly reduce mortality or prevent delirium but can be effective in treating delirium symptoms. While haloperidol may help with delirium symptoms, its use does not impact overall mortality or prevention, indicating a need for alternative strategies. Haloperidol treats delirium but does not affect mortality or prevention.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Cheng SL, Hsu TW, Kao YC, Yu CL, Thompson T, Carvalho AF, Stubbs B, Tseng PT, Hsu CW, Yang FC, Tu YK, Liang CS

Citation: Cheng SL, Hsu TW, Kao YC, et al. Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses. Critical care (London, England). 2025;29(1):126. doi:10.1186/s13054-025-05342-6

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.